Mirae Asset Global Investments’s Aura Biosciences AURA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$32.8K Buy
4,624
+1,312
+40% +$9.39K ﹤0.01% 1421
2026
Q1
$22.2K Buy
3,312
+226
+7% +$1.3K ﹤0.01% 1418
2025
Q4
$16.8K Buy
3,086
+684
+28% +$4.06K ﹤0.01% 1553
2025
Q3
$14.8K Buy
2,402
+7
+0.3% +$46 ﹤0.01% 1533
2025
Q2
$15K Buy
2,395
+739
+45% +$4.32K ﹤0.01% 1437
2025
Q1
$10.5K Sell
1,656
-9
-0.5% -$68 ﹤0.01% 1467
2024
Q4
$13.9K Buy
+1,665
New +$15.7K ﹤0.01% 1474
2024
Q2
Sell
-11,659
Closed -$108K 1610
2024
Q1
$108K Sell
11,659
-746
-6% -$6.18K ﹤0.01% 2364
2023
Q4
$110K Hold
12,405
﹤0.01% 2446
2023
Q3
$111K Buy
12,405
+746
+6% +$8.03K ﹤0.01% 2442
2023
Q2
$144K Hold
11,659
﹤0.01% 2433
2023
Q1
$108K Buy
+11,659
New +$121K ﹤0.01% 2433

Other funds holding AURA

Mirae Asset Global Investments's AURA Position: Q2 2026 in Review

Mirae Asset Global Investments increased its Aura Biosciences (AURA) stake by 40% in Q2 2026, buying an estimated $9.39K and bringing the position to 4,624 shares worth $32.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1421.

Mirae Asset Global Investments first reported a position in AURA in Q1 2023 and has held it in 12 quarters since. The position peaked at $144K in Q2 2023. 22 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Mirae Asset Global Investments held 4,624 shares of Aura Biosciences worth $32.8K as of Q2 2026.
  • Mirae Asset Global Investments bought 1,312 Aura Biosciences shares in Q2 2026, an estimated $9.39K.
  • Aura Biosciences made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1421 holding.
  • Mirae Asset Global Investments first reported a position in Aura Biosciences in Q1 2023 and has held it in 12 quarters since.
  • Mirae Asset Global Investments's Aura Biosciences position peaked at $144K in Q2 2023.
  • 22 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.